ky1044
mAbexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 28, 2019 (NCT03829501)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1/Phase 2
Mechanism of action
- Inducible T-cell costimulatorINHIBITOR
ICOS inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03829501 | Phase 1/Phase 2 (Phase 2) | Jan 28, 2019 | Kymab Limited |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kymab Limited | For profit | 1 | 1 | 1 | 2019 |
1 organizations
Page 1 / 1